PHVS Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

31.470

Open

31.270

VWAP

30.52

Vol

572.62K

Mkt Cap

1.97B

Low

30.000

Amount

17.48M

EV/EBITDA(TTM)

Total Shares

65.41M

1.74B

EV/OCF(TTM)

P/S(TTM)

Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

Events Timeline

(ET)

2026-04-20

07:00:00

Pharvaris Presents Deucrictibant Data at CIIC Conference

2026-04-02 (ET)

2026-04-02

07:00:00

Pharvaris to Submit NDA Application in 2026

2026-03-20 (ET)

2026-03-20

07:00:00

Pharvaris Publishes Two Studies on Deucrictibant

2026-03-11 (ET)

2026-03-11

07:00:00

Pharvaris Publishes Patient Experience Study Results for HAE Attacks

News

8.5

05-08seekingalpha

Pharvaris Prices Underwritten Offering of 3.87 Million Shares

8.5

05-08Newsfilter

Pharvaris Prices Underwritten Offering of 3,874,664 Shares

5.0

04-30Fool

Pharvaris Director Sells 7,100 Shares Under Rule 10b5-1 Plan

5.0

04-30NASDAQ.COM

Schikan Sells Shares of Pharvaris N.V.

5.0

04-13Fool

Pharvaris CEO Sells 23,333 Shares Amid Strong Stock Performance

9.5

04-02seekingalpha

Pharvaris Reports Q4 Loss of €46.7 Million

9 Analyst Rating

Wall Street analysts forecast PHVS stock price to rise

8 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

30.00

Averages

41.00

High

60.00

Current: 0.000

Low

30.00

Averages

41.00

High

60.00

BofA

Tazeen Ahmad

Neutral

maintain

$30 -> $31

AI Analysis

2026-05-10

New

Reason

BofA

Tazeen Ahmad

Price Target

$30 -> $31

AI Analysis

2026-05-10

New

maintain

Neutral

Reason

BofA analyst Tazeen Ahmad raised the firm's price target on Pharvaris to $31 from $30 and keeps a Neutral rating on the shares. The firm updated the company's model post the Q1 report.

JonesResearch

Debanjana Chatterjee

Buy

maintain

$48 -> $52

2026-04-15

Reason

JonesResearch

Debanjana Chatterjee

Price Target

$48 -> $52

2026-04-15

maintain

Buy

Reason

JonesResearch analyst Debanjana Chatterjee raised the firm's price target on Pharvaris to $52 from $48 and keeps a Buy rating on the shares, citing an increased peak sales projection for deucrictibant IR.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PHVS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Pharvaris NV (PHVS.O) is 0.00, compared to its 5-year average forward P/E of -6.63. For a more detailed relative valuation and DCF analysis to assess Pharvaris NV's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.63

Current PE

0.00

Overvalued PE

-4.38

Undervalued PE

-8.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.13

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-1.81

Undervalued EV/EBITDA

-6.45

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.93

Current PS

47.34

Overvalued PS

7.40

Undervalued PS

-5.53

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

best stock for swing traders tomorrow

Intellectia · 75 candidates

Price: $5.00 - $100.00Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceCrossAboveMA20One Day Rise Prob: >= 60Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

DNLI

Denali Therapeutics Inc

3.15B

MITK

Mitek Systems Inc

647.57M

SXC

SunCoke Energy Inc

552.33M

RDWR

Radware Ltd

1.10B

DHT

DHT Holdings Inc

2.91B

PHVS

Pharvaris NV

1.87B

단기 데이트레이닝에서 변동성이 5%로 예상되는 오늘 주식을 추천해줘

Intellectia · 11 candidates

Price: >= $5.00Price Change Pct: $3.00 - $7.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

ARVN

Arvinas Inc

724.68M

UNIT

Uniti Group Inc (Delaware)

2.39B

CALM

Cal-Maine Foods Inc

3.95B

ANGO

AngioDynamics Inc

492.14M

SMFG

Sumitomo Mitsui Financial Group, Inc

132.71B

HOPE

Hope Bancorp Inc

1.50B

which stocks will decrease this week

Intellectia · 42 candidates

Region: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceCrossDownMA5, PriceBelowMA20Week Price Change Pct: $-100.00 - $-2.00One Week Rise Prob: 0 - 40One Week Predict Return: -100.0% - -2.0%

Ticker

Name

Market Cap$

SYK

Stryker Corp

125.81B

VTR

Ventas Inc

39.03B

VEEV

Veeva Systems Inc

29.25B

RYTM

Rhythm Pharmaceuticals Inc

5.64B

DBX

Dropbox Inc

5.58B

CRSP

CRISPR Therapeutics AG

4.46B

which stocks show a great upside

Intellectia · 35 candidates

Analyst Consensus: Strong BuyBeta: LowRiskWeekly Average Turnover: >= 1,000,000Target Price Upside Potential: MoreAbovePriceMonth Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

LNG

Cheniere Energy Inc

44.62B

VNOM

Viper Energy Inc

14.18B

TTEK

Tetra Tech Inc

9.59B

PRAX

Praxis Precision Medicines Inc

8.57B

CORZ

Core Scientific Inc

5.64B

ALKS

Alkermes Plc

5.59B

Whales Holding PHVS

Deerfield Management Company, L.P.

Soleus Capital Management, L.P.

Sofinnova Investment, Inc.

Rock Springs Capital Management LP

Cormorant Asset Management, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Pharvaris NV (PHVS) stock price today?

The current price of PHVS is 30.09 USD — it has increased 1.38

What is Pharvaris NV (PHVS)'s business?

What is the price predicton of PHVS Stock?

Wall Street analysts forecast PHVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHVS is41.00 USD with a low forecast of 30.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Pharvaris NV (PHVS)'s revenue for the last quarter?

Pharvaris NV revenue for the last quarter amounts to -47.60M USD, decreased

What is Pharvaris NV (PHVS)'s earnings per share (EPS) for the last quarter?

Pharvaris NV. EPS for the last quarter amounts to -37954296.00 USD, decreased

How many employees does Pharvaris NV (PHVS). have?

Pharvaris NV (PHVS) has 129 emplpoyees as of May 11 2026.

What is Pharvaris NV (PHVS) market cap?

Today PHVS has the market capitalization of 1.97B USD.

PHVS Overview

PHVS Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding PHVS

Trading Trends

People Also Watch

Frequently Asked Questions

What is Pharvaris NV (PHVS) stock price today?

What is Pharvaris NV (PHVS)'s business?

What is the price predicton of PHVS Stock?

What is Pharvaris NV (PHVS)'s revenue for the last quarter?

What is Pharvaris NV (PHVS)'s earnings per share (EPS) for the last quarter?

How many employees does Pharvaris NV (PHVS). have?

What is Pharvaris NV (PHVS) market cap?